11521 RESULTS
COMMENT The FDA's decision to impose stricter regulations on in vitro "diagnostic" tests was anticipated, and this regulatory change will be beneficial for the Alzheimer's in vitro test ecosystem, as well as for clinicians and their patients.
COMMENT TGFꞵ1 is well-established as a contributor to cerebral amyloid angiopathy (CAA) (Wyss-Coray et al., 1997), and one of the earliest actions noted for TGFꞵ was induction of fibronectin expression (Ignotz and Massagué, 1986). It seems quite likely that this
COMMENT In 2019, a case report (Arboleda-Velasquez et al., 2019) of a person who was homozygous for the APOE3 Christchurch (R136S) mutation caught the attention of many researchers studying APOE and AD, including our group. It might delay cognitive decline by 25
COMMENT This paper is a masterpiece. It’s a fabulous review by the foremost proponent of the amyloid hypothesis, filled with valuable information for experts and beginners. mweiner 0
COMMENT In this Nature Aging article, the “eminence grise” of Alzheimer’s gives his perspective on the advent of AD in a concise and well-conceived way. I guess figures 1 and 2 will soon make their way into powerpoints of many colleagues in the field, showing the
COMMENT How do young investigators and newcomers in the AD field identify the most relevant findings when, every day, a large number of papers is published? They do not even have the time to read all of the new ones, much less easily judge which of these publicat
COMMENT The study by Huang and colleagues describes the evaluation of an AAV vector engineered to actively enter the brain via transferrin receptor (TfR)-mediated transcytosis. This route to enter the brain is well-established for biologics, such as antibodies, w
COMMENT Broadening the utilization of AAVs to treat CNS diseases is an exciting area of therapeutic development, but one that faces many challenges for clinical translation. This paper makes significant progress toward one such challenge in this field, which is t
COMMENT Gene transfer vectors derived from Adeno-Associated Virus (AAV) are the tools of choice for gene therapy (and gene editing) in the central nervous system. This paper is exciting because it shows, through a series of impeccably executed studies, that some
COMMENT APOE4 is the strongest risk factor for Alzheimer’s disease. APOE4 homozygosity was recently identified as a distinct, highly penetrant form of AD. However, a small percentage of APOE4 homozygotes live cognitively normal lives into their 80s and beyond (Fo
COMMENT In this very interesting paper Bretou et al. described the toxic effect produced by the genetic and pharmacologic inhibition of the γ-secretase complex. The authors described that these treatments increased the levels of APP-CTF inducing a dysfunction of
COMMENT This study is really exciting because it used longitudinal neuroimaging to understand factors that lead to tau accumulation in the brain and to later cognitive decline. We already knew that structural integrity of the locus coeruleus, a brainstem region o
COMMENT Laboratory-developed test (LDTS) in the current framework are an important tool to accelerate innovation, in particular in rapidly evolving diagnostic markets such as AD. Understanding risks/benefits, the target, performance in racial populations, and mul
COMMENT have already started direct-to-consumer selling of these tests, and in an earlier comment I and others
COMMENT An immunoassay, or any biomarker assay, needs to show acceptable, pre-defined performance criteria before it can be used for patient management or treatment selection, whether it is an IVD, LDT, or a research assay. The assay documentation must show resul
